COMPANY

EvoDenovo Inc.

EvoDenovo is advancing a precision biologics platform for depression and other CNS disorders, centered on engineered single-domain antibodies. From company website Source · Oct 12, 2026

Keywords: antibodies biologics

Location: Woburn, MA · source · Oct 13, 2026

Profile checked Oct 10, 2026

Funding and NIH signals

NIH award NIH awarded $687K (SBIR Phase II 5R44DA053844-04, continuation, notice Aug 24, 2026). NIH RePORTER 5R44DA053844-04 (Aug 24, 2026)
Evidence (1 event)
- Aug 24, 2026 · NIH RePORTER 5R44DA053844-04
  Organization: EVODENOVO, INC.; City/State: andover, MA; Project number: 5R44DA053844-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-24; FY total cost (award amount): 687310; Administering IC: National Institute on Drug Abuse; Project title: Development of small molecule therapeutics for mitigating opioid withdrawal syndrome; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Aug 24, 2026 Grant Government grant — SBIR: $687,310 (annual award, as published), announced Aug 24, 2026. Agency: NIH/NIDA. Source: government award database. source ↗
Aug 21, 2025 Grant Government grant — SBIR: $1.09M (annual award, as published), announced Aug 21, 2025. Agency: NIH/NIDA. Source: government award database. source ↗

Funding

Last 2 years.

Aug 24, 2026 Government grant — SBIR: $687,310 (annual award, as published), announced Aug 24, 2026. Agency: NIH/NIDA. Source: government award database. source ↗
Aug 21, 2025 Government grant — SBIR: $1.09M (annual award, as published), announced Aug 21, 2025. Agency: NIH/NIDA. Source: government award database. source ↗